CA2264718C - Coprecipites solides augmentant la biodisponibilite de substances lipophiles - Google Patents

Coprecipites solides augmentant la biodisponibilite de substances lipophiles Download PDF

Info

Publication number
CA2264718C
CA2264718C CA002264718A CA2264718A CA2264718C CA 2264718 C CA2264718 C CA 2264718C CA 002264718 A CA002264718 A CA 002264718A CA 2264718 A CA2264718 A CA 2264718A CA 2264718 C CA2264718 C CA 2264718C
Authority
CA
Canada
Prior art keywords
composition
tpgs
lipophilic substance
solid
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002264718A
Other languages
English (en)
Other versions
CA2264718A1 (fr
Inventor
Shimon Amselem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmos Corp
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11917696A external-priority patent/IL119176A/en
Priority claimed from US08/833,076 external-priority patent/US5891469A/en
Application filed by Pharmos Corp filed Critical Pharmos Corp
Publication of CA2264718A1 publication Critical patent/CA2264718A1/fr
Application granted granted Critical
Publication of CA2264718C publication Critical patent/CA2264718C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Abstract

On fait fondre des principes actifs lipophiles avec du succinate de tocophérol polyéthylèneglycol (TPGS) et un adjuvant de dispersion, de façon à obtenir des compositions de coprécipités secs solides convenant comme forme galénique orale. Les coprécipités de TPGS solides de principes actifs lipophiles permettent une meilleure libération des médicaments in vitro et présentent une meilleure biodisponibilité orale in vivo.
CA002264718A 1996-09-01 1997-08-27 Coprecipites solides augmentant la biodisponibilite de substances lipophiles Expired - Fee Related CA2264718C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL119176 1996-09-01
IL11917696A IL119176A (en) 1996-09-01 1996-09-01 Soluble coprecipitates for enhanced oral bioavailability of lipophilic substances
US08/833,076 1997-04-02
US08/833,076 US5891469A (en) 1997-04-02 1997-04-02 Solid Coprecipitates for enhanced bioavailability of lipophilic substances
PCT/US1997/015072 WO1998008490A1 (fr) 1996-09-01 1997-08-27 Coprecipites solides augmentant la biodisponibilite de substances lipophiles

Publications (2)

Publication Number Publication Date
CA2264718A1 CA2264718A1 (fr) 1998-03-05
CA2264718C true CA2264718C (fr) 2006-05-30

Family

ID=26323300

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002264718A Expired - Fee Related CA2264718C (fr) 1996-09-01 1997-08-27 Coprecipites solides augmentant la biodisponibilite de substances lipophiles

Country Status (5)

Country Link
EP (1) EP1017366A4 (fr)
JP (1) JP2001523221A (fr)
AU (1) AU730216B2 (fr)
CA (1) CA2264718C (fr)
WO (1) WO1998008490A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
IT1298731B1 (it) * 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche contenenti complessi di inclusione con melatonina
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
ATE311227T1 (de) * 1999-12-01 2005-12-15 Natco Pharma Ltd Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
DE60111352T2 (de) * 2000-01-20 2006-05-04 Supratek Pharma, Inc., Montreal Podophyllotoxin-zusammensetzungen
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
DE60213115T2 (de) 2001-10-19 2007-02-01 Isotechnika, Inc., Edmonton Synthese von cyclosporinanaloga
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
WO2004050068A1 (fr) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Compositions pharmaceutiques comprenant un compose medicamenteux respectivement basique, tensioactif et base respectivement acide hydrosoluble et tolerable physiologiquement
WO2004069180A2 (fr) 2003-01-31 2004-08-19 Smithkline Beecham Corporation Compositions solides de dispersion
WO2004073687A1 (fr) * 2003-02-19 2004-09-02 H. Lundbeck A/S Procede de preparation d'un agglomere par agglomeration a chaud
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
WO2005058290A2 (fr) * 2003-12-18 2005-06-30 Dsm Ip Assets B.V. Utilisation de vitamine e
JP4977611B2 (ja) * 2004-09-24 2012-07-18 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 新規な種類の界面活性剤様物質
WO2006039268A2 (fr) * 2004-09-30 2006-04-13 Eastman Chemical Company Formulations pharmaceutiques renfermant des molecules tpgs de vitamine e solubilisant des medicaments lipophiles sans inhibition importante de l'ecoulement et utilisation de telles formulations
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
US7446096B2 (en) * 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
US8067380B2 (en) 2005-12-19 2011-11-29 Industrial Technology Research Institute Glutathione-based delivery system
WO2008007728A1 (fr) * 2006-07-13 2008-01-17 Kaneka Corporation Préparation orale contenue dans une structure à membrane lipidique, et agent contre la fatigue comprenant une coenzyme comme ingrédient actif
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CN102083467B (zh) * 2008-03-11 2013-12-25 Aska制药株式会社 固体分散体及其药物组合物、以及它们的制备方法
CA2715018C (fr) 2008-03-20 2012-11-13 Virun, Inc. Derives de la vitamine e et leurs utilisations
BRPI0909187A2 (pt) 2008-03-20 2015-08-04 Virun Inc Emulsões incluindo tocoferol de derivados de peg
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
JPWO2010092925A1 (ja) * 2009-02-12 2012-08-16 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
CA2792330C (fr) 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion comportant un derive peg de vitamine e et un sucrose ester d'acide gras
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
ITMI20112042A1 (it) * 2011-11-10 2013-05-11 Eratech S R L Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere.
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
FR2999081B1 (fr) * 2012-12-06 2015-02-27 Hra Pharma Lab Dispersion solide d'un modulateur selectif du recepteur a la progesterone
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
HUP1300647A2 (hu) * 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
ES2938560T3 (es) * 2015-05-28 2023-04-12 Radius Pharmaceuticals Inc Formulaciones de cannabinoides estables
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CN110121337A (zh) * 2017-01-03 2019-08-13 受体控股公司 药用化合物和营养补充剂
AU2018221739A1 (en) * 2017-02-15 2019-08-29 Molecular Infusions, Llc Formulations
CN108245683B (zh) * 2018-01-26 2020-02-14 华中科技大学 一种具有p-糖蛋白抑制功能的抗肿瘤前药及制备方法
CA3161908A1 (fr) * 2019-12-20 2021-06-24 Michael Ambuehl Compositions pharmaceutiques comprenant du n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
DK4076404T3 (da) * 2019-12-20 2024-01-22 Intervet Int Bv Farmaceutisk pyrazolsammensætning
WO2023152672A1 (fr) * 2022-02-11 2023-08-17 Pierpaoli Exelyas S.R.L. Composition comprenant de la mélatonine à biodisponibilité élevée

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102078A (en) * 1961-01-13 1963-08-27 Eastman Kodak Co Water-dispersible vitamin preparations
US3673163A (en) * 1970-06-16 1972-06-27 Lilly Co Eli Pharmacological preparation containing an acronycine-polyvinylprrolidone coprecipitate
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4327080A (en) * 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
US4758427A (en) * 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
IT1255792B (it) * 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
CA2221145A1 (fr) * 1995-05-19 1996-11-21 Abbott Laboratories Formulations auto-emulsifiantes de medicaments lipophiles
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs

Also Published As

Publication number Publication date
JP2001523221A (ja) 2001-11-20
EP1017366A4 (fr) 2006-03-22
WO1998008490A1 (fr) 1998-03-05
AU730216B2 (en) 2001-03-01
EP1017366A1 (fr) 2000-07-12
CA2264718A1 (fr) 1998-03-05
AU4237397A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
CA2264718C (fr) Coprecipites solides augmentant la biodisponibilite de substances lipophiles
US5891469A (en) Solid Coprecipitates for enhanced bioavailability of lipophilic substances
AU722217B2 (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
JP2974409B2 (ja) 微粒子薬物組成物
EP1345597B1 (fr) Nanoparticules lipidiques amphiphiles destinees a l'incorporation de peptides et/ou proteines
US7687071B1 (en) Nanoparticulate core shell systems and the use thereof in pharmaceutical and cosmetic preparation
US6387409B1 (en) Composition and method of preparing microparticles of water-insoluble substances
US6001336A (en) Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof
Chen et al. Development of a solid supersaturatable self-emulsifying drug delivery system of docetaxel with improved dissolution and bioavailability
AU767896B2 (en) Use of nanodispersions in pharmaceutical end formulations
JP2012102135A (ja) 流動床噴霧乾燥によるナノ粒子製造方法
US20040248901A1 (en) Compositions containing itraconazole and their preparation methods
JP2001505928A (ja) シクロスポリン及び陰イオン性界面活性剤を含む固体医薬組成物
EP0702562A1 (fr) Composition pulverulente renfermant de la cyclosporine
KR20060041227A (ko) 점막점착성으로 제형화된 펩티드 또는 단백질 활성 성분을포함하는 다입자형 약제학적 투여 형태 및 이 약제학적투여 형태를 제조하는 방법
KR20070046089A (ko) 저-용해도 활성 성분을 위한 다입자 제약 투여 형태 및상기 제약 투여 형태의 제조 방법
JP2006511536A (ja) 水貧溶性薬物のバイオアベイラビリティーを改善する自由流動性固形製剤およびその製造方法
JP4721640B2 (ja) フェノフィブラートのナノ粒子製剤
JPH01502828A (ja) ペンタミジンを含有する医薬組成物
US20040180961A1 (en) Compositions and preparation methods for bioavailable oral aceclofenac dosage forms
EP0265226A2 (fr) Acetaminophène séché par pulvérisation
EP3854384A1 (fr) Formulation pharmaceutique comprenant de l'acétate d'abiratérone
KR102102098B1 (ko) 프로토파낙사디올을 함유하는 에멀전 예비농축액 조성물
IL119176A (en) Soluble coprecipitates for enhanced oral bioavailability of lipophilic substances
CA2251194C (fr) Compositions lipidiques solides de composes lipophiles pour ameliorer la biodisponibilite orale

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20090827